

Justin Stebbing

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2930229/justin-stebbing-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

198
papers

6,596
citations

40
h-index

77
g-index

243
ext. papers

8,301
ext. citations

8.9
avg, IF

6.46
L-index

#	Paper	IF	Citations
198	Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report.. <i>BMC Pulmonary Medicine</i> , 2022 , 22, 54	3.5	
197	Novel immunotherapeutic drugs for the treatment of lung cancer. <i>Current Opinion in Oncology</i> , 2022 , 34, 89-94	4.2	1
196	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.. <i>Oncologist</i> , 2022 ,	5.7	4
195	Developments in paediatric cancer care throughout the COVID-19 pandemic: Lessons from China.. <i>The Lancet Regional Health - Western Pacific</i> , 2022 , 100398	5	
194	Targeting ALK Rearrangements in NSCLC: Current State of the Art.. <i>Frontiers in Oncology</i> , 2022 , 12, 863463	5.3	1
193	Baricitinib as the treatment of choice for hospitalised individuals with COVID-19. <i>EClinicalMedicine</i> , 2022 , 49, 101493	11.3	0
192	Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 754768	5.3	4
191	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	2
190	A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers. <i>Frontiers in Immunology</i> , 2021 , 12, 762598	8.4	6
189	LMTK3 inhibition affects microtubule stability. <i>Molecular Cancer</i> , 2021 , 20, 53	42.1	1
188	What is the intermediate host species of SARS-CoV-2?. <i>Future Virology</i> , 2021 , 16, 153-156	2.4	4
187	Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study. <i>Journal of the American Geriatrics Society</i> , 2021 , 69, 1441-1447	5.6	30
186	Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC. <i>OncoTargets and Therapy</i> , 2021 , 14, 3409-3415	4.4	2
185	Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 465-476	4.4	0
184	Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 631-640	4.4	2
183	Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1245-1246	2.4	2
182	First-Line Treatment Options for PD-L1-Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 657545	5.3	0

181	-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes. <i>Frontiers in Oncology</i> , 2021 , 11, 680804	5.3	6
180	Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia. <i>Journal of the American Geriatrics Society</i> , 2021 , 69, 2752-2758	5.6	9
179	Immunotherapy-Related Cystitis: Case Report and Review of the Literature. <i>OncoTargets and Therapy</i> , 2021 , 14, 4321-4328	4.4	3
178	Circulating MicroRNAs in Small-bowel Neuroendocrine Tumors: A Potential Tool for Diagnosis and Assessment of Effectiveness of Surgical Resection. <i>Annals of Surgery</i> , 2021 , 274, e1-e9	7.8	11
177	Is asthma protective against COVID-19?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 866-868	9.3	72
176	The Emergence of Baricitinib: A Story of Tortoises Versus Hares. <i>Clinical Infectious Diseases</i> , 2021 , 72, 1251-1252	11.6	1
175	The LMTK-family of kinases: Emerging important players in cell physiology and pathogenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021 , 1867, 165372	6.9	7
174	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 443-452	9.7	8
173	SCIRT lncRNA Restrains Tumorigenesis by Opposing Transcriptional Programs of Tumor-Initiating Cells. <i>Cancer Research</i> , 2021 , 81, 580-593	10.1	7
172	JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. <i>Science Advances</i> , 2021 , 7,	14.3	97
171	SARS-CoV-2 (COVID-19) superspreader events. <i>Journal of Infection</i> , 2021 , 82, 36-40	18.9	50
170	Reducing transmission of SARS-CoV-2 with intranasal prophylaxis. <i>EBioMedicine</i> , 2021 , 63, 103170	8.8	1
169	Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 371-380	9.7	66
168	Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 107-111	11.5	68
167	Asthma phenotypes, comorbidities, and disease activity in COVID-19: The need of risk stratification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 955-956	9.3	4
166	Response to Cottu, Bozec, Basse, and Paoletti. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 344-345	9.7	7
165	Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 1349-1351	35.1	9
164	Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3858-3860	4.4	0

163	Immunogenicity after six months of BNT162b2 vaccination in frail or disabled nursing home residents: the COVID-A Study. <i>Journal of the American Geriatrics Society</i> , 2021 ,	5.6	2
162	A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma.. <i>Frontiers in Oncology</i> , 2021 , 11, 778637	5.3	
161	CNS penetration of potential anti-COVID-19 drugs. <i>Journal of Neurology</i> , 2020 , 267, 1880-1882	5.5	20
160	Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. <i>EMBO Molecular Medicine</i> , 2020 , 12, e12697	12	135
159	Lessons to Europe from China for cancer treatment during the COVID-19 pandemic. <i>British Journal of Cancer</i> , 2020 , 123, 7-8	8.7	3
158	A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. <i>OncImmunity</i> , 2020 , 9, 1781333	7.2	9
157	COVID-19: combining antiviral and anti-inflammatory treatments. <i>Lancet Infectious Diseases</i> , 2020 , 20, 400-402	25.5	685
156	Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1070-1080	2.2	9
155	805 Safety and emerging evidence of immune modulation of the live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours 2020 , 8, A854-A854		3
154	PIK3C β expression by fibroblasts promotes triple-negative breast cancer progression. <i>Journal of Clinical Investigation</i> , 2020 , 130, 3188-3204	15.9	13
153	Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. <i>Lancet, The</i> , 2020 , 395, e30-e31	4.0	848
152	The Use of Transdermal Estrogen in Castrate-resistant, Steroid-refractory Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e217-e223	3.3	2
151	Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. <i>Oncogene</i> , 2020 , 39, 1846-1859	9.2	15
150	A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1505-1511	4.1	15
149	Sports balls as potential SARS-CoV-2 transmission vectors. <i>Public Health in Practice</i> , 2020 , 1, 100029	2.6	3
148	Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020 , 10, 549168	5.3	2
147	The structure-function relationship of oncogenic LMTK3. <i>Science Advances</i> , 2020 , 6,	14.3	7
146	Reply to letter to the editor: baricitinib and toxicity is a rare occurrence. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1371-1372	4.1	0

145	Baricitinib for COVID-19: a suitable treatment? - Authors' reply. <i>Lancet Infectious Diseases, The</i> , 2020 , 20, 1013-1014	25.5	43
144	Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. <i>Frontiers in Endocrinology</i> , 2019 , 10, 245	5.7	75
143	SSB1/SSB2 Proteins Safeguard B Cell Development by Protecting the Genomes of B Cell Precursors. <i>Journal of Immunology</i> , 2019 , 202, 3423-3433	5.3	3
142	Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. <i>Clinical Cancer Research</i> , 2019 , 25, 4255-4263	12.9	133
141	Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping. <i>Communications Biology</i> , 2019 , 2, 315	6.7	42
140	Thermosensitive Liposome-Mediated Drug Delivery in Chemotherapy: Mathematical Modelling for Spatio-temporal Drug Distribution and Model-Based Optimisation. <i>Pharmaceutics</i> , 2019 , 11,	6.4	4
139	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 134, 39-45	7	129
138	Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 454-458	8.9	6
137	A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 81, 505-514	3.5	23
136	Image-guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF-labelled lipids and topotecan to visualise the effects of hyperthermia in tumours. <i>Journal of Controlled Release</i> , 2018 , 280, 87-98	11.7	48
135	LMTK3 confers chemo-resistance in breast cancer. <i>Oncogene</i> , 2018 , 37, 3113-3130	9.2	19
134	Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 531-541	3.5	4
133	Efficacy and safety of the trastuzumab biosimilar candidate CT-P6. <i>Future Oncology</i> , 2018 , 14, 1909-1919	3.6	8
132	TGF- β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. <i>Nature Communications</i> , 2018 , 9, 1845	17.4	61
131	The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of indolent Stage IV disease (Stage IV indolent).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1019-1019	2.2	3
130	Pharmacokinetics of CT-P6 and reference trastuzumab by clinical factors in patients with HER2 positive early-stage breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 591-591	2.2	2
129	The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas. <i>Oncotarget</i> , 2018 , 9, 11371-11376	3.3	1
128	Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?. <i>Oncotarget</i> , 2018 , 9, 9456-9467	3.3	6

127	Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments. <i>Oncotarget</i> , 2018 , 9, 12805-12811	3.3	2
126	Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. <i>Oncotarget</i> , 2018 , 9, 19006-19013	3.3	71
125	Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy. <i>Oncotarget</i> , 2018 , 9, 6007-6014	3.3	
124	Enhanced Sensitivity of Lymphoid Cells to Ethanol ADH Acetaldehyde Toxicity; Implications for GDEPT and Adoptive T Cell Therapy. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2018 , 16, 118-123	0.4	
123	Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. <i>Oncotarget</i> , 2018 , 9, e1396403	7.2	34
122	Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018 , 2018,	1.4	15
121	Human NK Cells Develop an Exhaustion Phenotype During Polar Degranulation at the Hyphal Synapse. <i>Frontiers in Immunology</i> , 2018 , 9, 2344	8.4	9
120	Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018 , 9, 275-281	2.8	35
119	Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans. <i>Oncotarget</i> , 2018 , 9, 17589-17596	3.3	2
118	Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma. <i>Molecular Cancer</i> , 2018 , 17, 132	42.1	39
117	Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. <i>Clinical Cancer Research</i> , 2017 , 23, 88-96	12.9	151
116	The relationship between ethnicity, social deprivation and late presentation of colorectal cancer. <i>Cancer Epidemiology</i> , 2017 , 47, 88-93	2.8	12
115	Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors. <i>Cell Reports</i> , 2017 , 18, 1687-1698	10.6	10
114	Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR. <i>Nucleic Acids Research</i> , 2017 , 45, 4401-4412	20.1	12
113	The need for multidisciplinary in specialist training to optimize future patient care. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 508-517	19.4	4
112	CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. <i>Lancet Oncology</i> , 2017 , 18, 917-928	21.7	62
111	The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 2246-2256	6.1	21
110	The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017 , 66, 338-346	13.4	191

109	Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 510-510	2.2	4
108	Surgery in combination with peptide receptor radionuclide therapy is effective in metastatic neuroendocrine tumors and is definable by blood gene transcript analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15697-e15697	2.2	
107	miR-515-5p controls cancer cell migration through MARK4 regulation. <i>EMBO Reports</i> , 2016 , 17, 570-84	6.5	72
106	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogenic primary and metastatic lung cancer: Implications for immunotherapy. <i>Oncolmmunology</i> , 2016 , 5, e1213934	7.2	53
105	Investigating miRNA-mRNA regulatory networks using crosslinking immunoprecipitation methods for biomarker and target discovery in cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 1155-1162	3.8	6
104	Strategies in functional proteomics: Unveiling the pathways to precision oncology. <i>Cancer Letters</i> , 2016 , 382, 86-94	9.9	7
103	Melatonin: resetting the clock of cancer progression?. <i>Lancet Oncology, The</i> , 2016 , 17, 23-4	21.7	7
102	LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5. <i>Cancer Letters</i> , 2016 , 372, 137-46	9.9	23
101	TP53 regulates miRNA association with AGO2 to remodel the miRNA-mRNA interaction network. <i>Genome Research</i> , 2016 , 26, 331-41	9.7	43
100	Spatially resolved profiling of colorectal cancer lipid biochemistry via DESI imaging mass spectrometry to reveal morphology-dependent alterations in fatty acid metabolism.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15104-e15104	2.2	2
99	Programmed cell death (PD-1) ligands expression in gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs): relationship with angiogenesis and clinical outcome.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15658-e15658	2.2	3
98	ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation. <i>Oncotarget</i> , 2016 , 7, 27599-612	3.3	20
97	Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. <i>Oncotarget</i> , 2016 , 7, 28556-69	3.3	16
96	MicroRNAs associated with small bowel neuroendocrine tumors and their metastases.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11598-11598	2.2	
95	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogenic primary and metastatic lung cancer (LC): Implications for immunotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11601-11601	2.2	1
94	Garlic: a stake through the heart of cancer?. <i>Lancet Oncology, The</i> , 2016 , 17, 879-880	21.7	6
93	Turmeric: a spice for life?. <i>Lancet Oncology, The</i> , 2016 , 17, 1639	21.7	2
92	Gene of the month: Axl. <i>Journal of Clinical Pathology</i> , 2016 , 69, 391-7	3.9	22

91	Aloe vera, a natural cancer soother?. <i>Lancet Oncology, The</i> , 2016 , 17, 421	21.7	6
90	Proteome-wide dataset supporting functional study of tyrosine kinases in breast cancer. <i>Data in Brief</i> , 2016 , 7, 740-6	1.2	3
89	Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2016 , 115, 789-96	8.7	38
88	The role of TP53 in miRNA loading onto AGO2 and in remodelling the miRNA-mRNA interaction network. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S15	4.0	22
87	microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 1389-404	7.5	80
86	Artemisia: a divine dart against cancer?. <i>Lancet Oncology, The</i> , 2015 , 16, 759-60	21.7	
85	Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics. <i>Molecular and Cellular Proteomics</i> , 2015 , 14, 2479-92	7.6	14
84	The germline of the malaria mosquito produces abundant miRNAs, endo-siRNAs, piRNAs and 29-nt small RNAs. <i>BMC Genomics</i> , 2015 , 16, 100	4.5	38
83	Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis. <i>American Journal of Gastroenterology</i> , 2015 , 110, 768-9	0.7	2
82	Probiotics and cancer: ready for meal time?. <i>Lancet Oncology, The</i> , 2015 , 16, 371-2	21.7	
81	Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S37	4.0	41
80	Cannabis and cancer: reality or pipe dream?. <i>Lancet Oncology, The</i> , 2015 , 16, 1291-2	21.7	6
79	Gene of the month: NANOG. <i>Journal of Clinical Pathology</i> , 2015 , 68, 763-5	3.9	9
78	Noncoding RNAs and the control of signalling via nuclear receptor regulation in health and disease. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2015 , 29, 529-43	6.5	11
77	mutation screening in human glioblastomas. <i>Future Science OA</i> , 2015 , 1,	2.7	1
76	Mammosphere formation assay from human breast cancer tissues and cell lines. <i>Journal of Visualized Experiments</i> , 2015 ,	1.6	63
75	Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. <i>Clinical Chemistry</i> , 2015 , 61, 974-82	5.5	129
74	LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer. <i>Cell Reports</i> , 2015 , 12, 837-49	10.6	16

73	Black cohosh, hot flushes, and breast cancer. <i>Lancet Oncology, The</i> , 2015 , 16, 137-8	21.7	11
72	The many-faced KSR1: a tumor suppressor in breast cancer. <i>Oncoscience</i> , 2015 , 2, 669-70	0.8	
71	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology, The</i> , 2014 , 15, 406-14	21.7	566
70	Uncaria tomentosa, the cat's whiskers or claws?. <i>Lancet Oncology, The</i> , 2014 , 15, 1299-300	21.7	2
69	Electrotherapy: enlightening modern medicine. <i>Lancet Oncology, The</i> , 2014 , 15, 1060-1	21.7	1
68	Cancer: Where were we, where are we, where are we going. <i>Medico-Legal Journal</i> , 2014 , 82, 57-66	1.4	
67	Crystals and cancer: good vibrations or bad intentions?. <i>Lancet Oncology, The</i> , 2014 , 15, 263-4	21.7	
66	Patient-derived xenografts for individualized care in advanced sarcoma. <i>Cancer</i> , 2014 , 120, 2006-15	6.4	118
65	The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin □ <i>Science Signaling</i> , 2014 , 7, ra58	8.8	26
64	Whole genome sequence analysis suggests intratumoral heterogeneity in dissemination of breast cancer to lymph nodes. <i>PLoS ONE</i> , 2014 , 9, e115346	3.7	13
63	Reply to S.E. Krown et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2514-5	2.2	3
62	Hyperthermia in cancer: is it coming of age?. <i>Lancet Oncology, The</i> , 2014 , 15, 565-6	21.7	13
61	MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. <i>Gastroenterology</i> , 2014 , 146, 268-77.e18	13.3	125
60	MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. <i>PLoS ONE</i> , 2014 , 9, e85935	3.7	20
59	Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. <i>PLoS ONE</i> , 2014 , 9, e90948	3.7	47
58	Circulating free DNA in the management of breast cancer. <i>Annals of Translational Medicine</i> , 2014 , 2, 3	3.2	16
57	Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. <i>Anticancer Research</i> , 2014 , 34, 1531-5	2.3	40
56	Chocolate: delicious beauty or harmful beast?. <i>Lancet Oncology, The</i> , 2013 , 14, 457-8	21.7	7

55	Milk thistle: early seeds of potential. <i>Lancet Oncology, The</i> , 2013 , 14, 929-30	21.7	16
54	Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2261-72	6.1	17
53	The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study. <i>PLoS ONE</i> , 2013 , 8, e62543	3.7	28
52	Ginger: the root of cancer therapy?. <i>Lancet Oncology, The</i> , 2012 , 13, 235-6	21.7	11
51	LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 537-44	4.4	29
50	An overview of drug development for metastatic breast cancer. <i>British Journal of Nursing</i> , 2012 , 21, S18-27	12	
49	LMTK3 polymorphism in patients with metastatic colon cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 471-471	2.2	4
48	Antioxidants and cancer. <i>Lancet Oncology, The</i> , 2011 , 12, 996	21.7	12
47	HBV and lymphoma: HIV matters. <i>Aids</i> , 2011 , 25, 274-275	3.5	
46	Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. <i>Blood</i> , 2011 , 118, 271-5	2.2	57
45	Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. <i>Nature Medicine</i> , 2011 , 17, 715-9	50.5	101
44	Epidermal growth factor receptor status in early stage breast cancer is associated with cellular proliferation but not cross-talk. <i>Journal of Clinical Pathology</i> , 2011 , 64, 829-31	3.9	5
43	Primary esophageal carcinoma in the era of highly active antiretroviral therapy. <i>Archives of Internal Medicine</i> , 2010 , 170, 203-7		14
42	Reply to Z.S. Lalmahomed et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e290-e290	2.2	1
41	A meta-analysis of transient elastography for the detection of hepatic fibrosis. <i>Journal of Clinical Gastroenterology</i> , 2010 , 44, 214-9	3	154
40	No evidence for a polyomavirus association or aetiology in AIDS-associated nonsmall cell lung cancer. <i>Aids</i> , 2010 , 24, 1221-3	3.5	4
39	Circulating sphingosine-1-phosphate inversely correlates with chemotherapy-induced weight gain during early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 543-9	4.4	6
38	Kinases as targets in the treatment of solid tumors. <i>Cellular Signalling</i> , 2010 , 22, 984-1002	4.9	71

37	The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. <i>Lung Cancer</i> , 2009 , 63, 94-7	5.9	117
36	BIK (Bcl2-Interacting Killer) CpG Methylation Status in Multiple Myeloma Patients: a Potential Predictor of Relapsed/Refractory Disease.. <i>Blood</i> , 2009 , 114, 2397-2397	2.2	
35	Use of antidepressants and risk of cancer in individuals infected with HIV. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2305-10	2.2	4
34	Cardiotoxicity and anthracyclines. <i>Breast Cancer Research and Treatment</i> , 2008 , 107, 451-3	4.4	5
33	Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments. <i>Cancer</i> , 2008 , 112, 955-61	6.4	6
32	The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer. <i>Cancer</i> , 2008 , 113, 1489-95	6.4	14
31	HIV-associated multicentric Castleman's disease. <i>American Journal of Hematology</i> , 2008 , 83, 498-503	7.1	67
30	Methylation Status of SMURF2 and Correlation with Clinical Parameters in Patients with Multiple Myeloma. <i>Blood</i> , 2008 , 112, 4472-4472	2.2	
29	Snk/Plk2 Methylation Is a Frequent Event in Patients with Multiple Myeloma. <i>Blood</i> , 2008 , 112, 4479-4479	2.2	
28	Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. <i>Cancer</i> , 2007 , 109, 93-9	6.4	38
27	Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2230-5	2.2	8
26	Virological failure and subsequent resistance profiles in individuals exposed to atazanavir. <i>Aids</i> , 2007 , 21, 1826-8	3.5	5
25	Translational review of AIDS-related Kaposi's sarcoma. <i>Update on Cancer Therapeutics</i> , 2007 , 2, 53-60		
24	Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals. <i>Expert Review of Anticancer Therapy</i> , 2006 , 6, 335-41	3.5	12
23	AIDS-related cancers, Part II: Systemic and cerebral lymphomas. <i>Community Oncology</i> , 2006 , 3, 34-41		
22	AIDS associated malignancies. <i>Update on Cancer Therapeutics</i> , 2006 , 1, 221-234		
21	Opposing roles of dendritic cell subsets in HIV-1 infection. <i>Blood</i> , 2006 , 108, 1785-1786	2.2	1
20	New therapies for hepatitis infection. <i>Future Virology</i> , 2006 , 1, 533-535	2.4	

19	AIDS-related cancers, Part I: Kaposi's sarcoma and cervical cancer. <i>Community Oncology</i> , 2005 , 2, 507-511		
18	Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events. <i>Clinical Infectious Diseases</i> , 2005 , 41, 906-11	11.6	32
17	Paclitaxel for AIDS-associated Kaposi's sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2005 , 5, 215-9	3.5	18
16	The rationale and development of new drugs to treat HIV infection. <i>Medicinal Chemistry</i> , 2005 , 1, 635-42	1.8	4
15	A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART). <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 53, 501-5	5.1	13
14	Studies on the allostimulatory function of dendritic cells from HCV-HIV-1 co-infected patients. <i>Cell Research</i> , 2004 , 14, 251-6	24.7	9
13	Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma. <i>International Journal of Cancer</i> , 2004 , 108, 473-4	7.5	21
12	The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma. <i>International Journal of Cancer</i> , 2004 , 108, 631-3	7.5	29
11	All for CD91 and CD91 for all. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 53, 1-3	5.1	11
10	Kaposi's sarcoma as a model for cancer immunotherapy. <i>Trends in Molecular Medicine</i> , 2004 , 10, 187-93	11.5	7
9	Where does HIV live?. <i>New England Journal of Medicine</i> , 2004 , 350, 1872-80	59.2	125
8	Antibody-targeted MHC complex-directed expansion of HIV-1- and KSHV-specific CD8+ lymphocytes: a new approach to therapeutic vaccination. <i>Blood</i> , 2004 , 103, 1791-5	2.2	14
7	The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected "true" long-term nonprogressors. <i>Blood</i> , 2003 , 101, 4000-4	2.2	51
6	Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor. <i>Blood</i> , 2003 , 102, 1806-14	2.2	42
5	New insights into the immunology and evolution of HIV. <i>Cell Research</i> , 2003 , 13, 1-7	24.7	21
4	Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo, and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcoma. <i>Aids</i> , 2003 , 17, 1998-2000	3.5	8
3	Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients		4
2	Point-of-care serological assays for SARS-CoV-2 in a UK hospital population: potential for enhanced case finding		4

1 Mutational landscapes of normal breast during age and pregnancy determine cancer risk

2